Clinical Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 (CimetrA)
Corona Virus Infection, Covid19, SARS-CoV Infection
About this trial
This is an interventional treatment trial for Corona Virus Infection focused on measuring corona, covid19, covid, coronavirus, corona virus infection, sars-cov-2
Eligibility Criteria
Inclusion Criteria:
- Confirmed SARS-CoV-2 infection (according to nationally authorized laboratory criteria)
- Hospitalized patient with COVID-19 of moderate stable or worsening severity not requiring ICU admission.
- Age: 18 years old and above.
- Subjects must be under observation or admitted to a controlled facility or hospital (home quarantine is not sufficient).
- Ability to receive treatment by spray into the oral cavity
Exclusion Criteria:
- Tube feeding or parenteral nutrition.
- Patients with scores 5 or above per the Ordinal Scale for Clinical Improvement published by the WHO. (i.e., who need oxygen supply beyond use of nozzles or simple mask)
- Need for admission to ICU during the present hospitalization at any time prior to completion of the recruitment to the study.
- Any condition which, in the opinion of the Principal Investigator, would prevent full participation in this trial or would interfere with the evaluation of the trial endpoints.
Sites / Locations
- Nazareth Hospital EMMS
- Rambam Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
Arm 1 - CimetrA-1
Arm 2 - CimetrA-2
Arm 3 - Placebo
a total dose containing a combination of Artemisinin 12 mg, Curcumin 40 mg, Boswellia 30 mg, and Vitamin C 120 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
a total dose containing a combination of Artemisinin 8.4 mg, Curcumin 28 mg, Boswellia 21 mg, and Vitamin C 84 mg in spray administration - divided into 4 separate doses given as an add on therapy, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).
composed of the same solvent but without active ingredients, given as an add on therapy in spray administration, 4 doses over 48 hours (day 1 and day 2), twice a day (morning and evening).